Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.
MRD作为抗白药物疗效标志,被用评估患者危险,在某些例中也用调整治疗强度。
Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.
MRD作为抗白药物疗效标志,被用评估患者危险,在某些例中也用调整治疗强度。
声:例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。